🔗 Share this article

As the US proceeds with unprecedented adjustments to its immunization guidelines, one figure appears unexpectedly: Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by questioning coronavirus shots during the pandemic and has focused upon alleged fatalities after Covid vaccination in her short time at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Program

Health officials had intended to reveal major changes to the pediatric immunization program recently, aligning the US with the Danish national calendar, according to reports – a major change that would place the US at odds with much of the international standard with little proof for benefit. The announcement has been postponed until the coming year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to present at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to head the office this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a renewed priority upon rolling back previously authorized immunizations at the FDA.

The new acting director has often pushed for halting certain pediatric vaccine recommendations in the US in order to be more like the Danish model, a country with comprehensive healthcare and a population roughly the population of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccines – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Background

The appointee has no obvious experience in drug development, oversight or leadership, which has been typical for previous heads of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a large organization. She lacks background in drug approvals.”

Past commissioners of CBER would “understand legal statutes and the research of medication creation”, noted a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that previous people who led CBER have had.”

The drug center has an immense range of responsibilities at the agency, she pointed out.

“The public just pays attention on the novel medication approvals, but the off-patent medication office approves thousands of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and so forth, and each of these need to be looked after,” she said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial management element to the job, which oversees over 5,000 staff members. “It’s a massive administrative position, if you perform it correctly,” she added.

Response and Disputed Programs

In response to questions about Dr. Høeg's fitness for the role and whether this appointment indicates greater collaboration among regulatory chiefs on vaccines, a representative responded that the “inquiries rely on flawed presumptions”.

“Her experience is consistent with the duties of her role,” the spokesperson said, pointing to the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a contentious rapid therapy clearance system that allegedly concerned her former heads. “By what process are these drugs being chosen for this fast-track system? Who takes the calls?” Dr. Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

Overall, he stated, “the Food and Drug Administration appears to be shifting towards less stringent rules of all drugs, with the exception of shots.”

Documented History on Immunizations

With immunizations, Høeg has a more documented, if troubling, past, critics said. She published a research paper using unconfirmed public submissions to estimate the frequency of heart inflammation after COVID-19 vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Among her “policy goals” for the new government featured altering rules for new vaccines and halting “optional” immunizations, she said after the election on a online show. At the agency, Dr. Høeg has reportedly proposed excluding adolescent males from receiving COVID-19 vaccinations.

“She is an all-around ideologue who commences with her beliefs and tailors the evidence to accommodate the data in a extremely misleading, dishonest way,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|